Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) vs Zoetis Inc (ZTS) Price & Performance

Direxion Daily 20 Year Treasury Bull 3X SharesTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Direxion Daily 20 Year Treasury Bull 3X Shares vs Zoetis Inc — how do they compare? Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.73 (market cap $2.03B), while Zoetis Inc trades at $74.33 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 14.9× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Zoetis Inc pays a 2.9% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days and Zoetis Inc for 70 Days on average.

TMFZTS
Market Cap
$2.03B$30.20B
Volume
12,241,6646,175,327
Sector
Fixed IncomeHealth
52-Week High
$44.14$147.53
52-Week Low
$25.19$69.09
Typical Hold Time
28 Days70 Days
Enterprise Value
—$37.76B
Dividend Yield
—2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Direxion Daily 20 Year Treasury Bull 3X Shares

TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $25.64 with a 1.61% daily gain amid elevated volume. Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators are neutral. The ETF saw increased trading activity with over 5.2 million shares changing hands, as reported by Defense World on October 3, 2026. A dividend of $0.35 is scheduled for payment on September 29, 2026.

The outlook for TMF remains tied to long-term Treasury bond performance, with current technical weakness suggesting near-term pressure. Investment opportunity exists for investors bullish on declining long-term interest rates, but risks include interest rate volatility and the leveraged nature of the ETF amplifying losses. Market sentiment appears mixed given conflicting technical signals.

Zoetis Inc

Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.

Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TMF
100% Buy0% Sell
Avg holding period · 28 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Direxion Daily 20 Year Treasury Bull 3X Shares

TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.

Read more on TMF →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →